{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:24:37Z","timestamp":1782962677742,"version":"3.54.5"},"reference-count":21,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,6,22]],"date-time":"2009-06-22T00:00:00Z","timestamp":1245628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Objective\u2002<\/jats:bold> To identify risk factors for in\u2010hospital mortality in patients treated for visceral leishmaniasis (VL) in Uganda.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Retrospective analysis of VL patients\u2019 clinical data collected for project monitoring by M\u00e9decins Sans Fronti\u00e8res in Amudat, eastern Uganda.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Between 2000 and 2005, of 3483 clinically suspect patients, 53% were confirmed with primary VL. Sixty\u2010two per cent were children &lt;16\u2003years of age with a male\/female ratio of 2.2. The overall case\u2010fatality rate during pentavalent antimonial (<jats:italic>n<\/jats:italic>\u2003=\u20031641) or conventional amphotericin B treatment (<jats:italic>n<\/jats:italic>\u2003=\u2003217) was 3.7%. There was no difference in the case\u2010fatality rate between treatment groups (<jats:italic>P<\/jats:italic>\u2003&gt;\u20030.20). The main risk factors for in\u2010hospital death identified by a multivariate analysis were age &lt;6\u2003years and &gt;15\u2003years, concomitant tuberculosis or hepatopathy, and drug\u2010related adverse events. The case\u2010fatality rate among patients &gt;45\u2003years of age was strikingly high (29.0%).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Subgroups of VL patients at higher risk of death during treatment with drugs currently available in Uganda were identified. Less toxic drugs should be evaluated and used in these patients.<\/jats:p>","DOI":"10.1111\/j.1365-3156.2009.02305.x","type":"journal-article","created":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T01:51:36Z","timestamp":1245721896000},"page":"910-917","source":"Crossref","is-referenced-by-count":53,"title":["Risk factors for in\u2010hospital mortality of visceral leishmaniasis patients in eastern Uganda"],"prefix":"10.1111","volume":"14","author":[{"given":"Yolanda","family":"Mueller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawson B.","family":"Mbulamberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Odermatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Loutan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chappuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,8,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1086\/507530"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2001.00795.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.12.5973-5977.2005"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1086\/381203"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.1.111-126.2006"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4269\/ajtmh.1999.61.766","article-title":"High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type\u20101\u2010infected patients","volume":"61","author":"Delgado J","year":"1999","journal-title":"American Journal of Tropical Medicine and Hygiene"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2004.03.004"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(02)00347-X"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182004005955"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2003.01088.x"},{"key":"e_1_2_6_12_1","first-page":"388","article-title":"Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya","volume":"79","author":"Moore E","year":"2001","journal-title":"Bulletin of the World Health Organization"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl342"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1179\/136485908X252142"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70296-6"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(01)90110-5"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1086\/505217"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-7-199604010-00007"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/380971"},{"key":"e_1_2_6_20_1","first-page":"14","article-title":"Observations on amphotericin B treatment of kala\u2010azar given in a rural set up in Bihar, India","volume":"113","author":"Thakur CP","year":"2001","journal-title":"Indian Journal of Medical Research"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3156.2000.00555.x"},{"key":"e_1_2_6_22_1","volume-title":"Visceral leishmaniasis control","author":"WHO","year":"1996"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-3156.2009.02305.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-3156.2009.02305.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T02:58:22Z","timestamp":1697252302000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-3156.2009.02305.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1365-3156.2009.02305.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-3156.2009.02305.x","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}